On November 4, 2025, Sky Labs announced that it has received investment from OMRON Ventures, which is part of the Omron Group and based in Minato-ku, Tokyo. This investment is not just financial—it represents a deeper strategic connection between the two companies aimed at growing their business on a global scale.
Health Technology Insights: Hippocratic AI Selects Fivetran to Power Trusted Data Infrastructure for AI in Healthcare
At the same time, Sky Labs and OMRON Healthcare Co., Ltd., based in Muko, Kyoto, and led by President and CEO Ayumu Okada, signed a Memorandum of Understanding (MoU). This agreement strengthens their collaboration in the global blood pressure monitoring market.
The partnership is built on Sky Labs’ innovative technology, specifically their cuffless ring-shaped blood pressure monitor called “CART BP.” This device is the first of its kind worldwide and is already available commercially. One of the main advantages of CART BP is that it continuously tracks blood pressure data throughout the day, during sleep, and at night, helping to identify trends and changes that may not be detected during regular doctor or clinic visits.
Health Technology Insights: Wolters Kluwer Launches Ovid Synthesis Expert AI
In 2024, the two companies had already signed an MoU covering global sales and business development of CART BP, along with an agreement for earlier products in the Japanese market. OMRON Healthcare leads the blood pressure monitoring market in more than 130 countries and regions. As of 2025, the company has sold over 400 million units worldwide and continues to develop innovative solutions for accurate and ongoing blood pressure management at home.
Jack Byunghwan Lee, CEO of Sky Labs, said, “This partnership shows that Sky Labs’ technology is recognized as both clinically effective and commercially promising on a global level. By working with OMRON Healthcare, which already leads the blood pressure monitoring market, we aim to drive innovation in global healthcare and enhance chronic disease management worldwide.”
Health Technology Insights: Cardiosense Shows AI Heart Failure Data at Transcatheter Cardiovascular Therapeutics 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
